Anaptysbio, inc (ANAB)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Revenue from Contract with Customer, Excluding Assessed Tax

15,000

3,000

0

5,000

0

0

5,000

0

0

3,000

0

7,000

0

2,754

3,214

5,850

4,866

Operating expenses:
Research and development

20,968

21,426

29,931

27,350

20,631

15,920

17,883

10,583

11,810

7,606

6,697

7,205

7,935

5,016

3,282

2,335

4,786

General and administrative

4,285

3,832

3,814

4,307

4,141

3,743

4,004

3,832

3,947

2,545

2,390

2,350

2,053

912

1,007

1,152

1,219

Total operating expenses

25,253

25,258

33,745

31,657

24,772

19,663

21,887

14,415

15,757

10,151

9,087

9,555

9,988

5,928

4,289

3,487

6,005

Loss from operations

-10,253

-22,258

-33,745

-26,657

-24,772

-19,663

-16,887

-14,415

-15,757

-7,151

-9,087

-2,555

-9,988

-3,174

-1,075

2,363

-1,139

Other income (expense), net:
Interest expense

0

200

240

281

320

365

400

436

451

456

452

439

428

111

116

116

115

Change in fair value of liability for preferred stock warrants

-

-

-

-

-

-

-

-

-

0

0

0

1,366

1,091

47

-3

-379

Interest income

1,897

2,282

2,757

2,957

2,988

2,834

1,369

1,297

1,185

862

358

281

122

-

-

-

-

Other income, net

94

-109

144

-41

7

8

-40

-64

-63

-116

91

29

225

-329

123

72

-13

Total other income (expense), net

1,991

1,973

2,661

2,635

2,675

2,477

929

797

671

290

-3

-129

-1,447

-1,404

-40

-41

251

Loss before income taxes

-8,262

-20,285

-31,084

-24,022

-22,097

-17,186

-15,958

-13,618

-15,086

-

-

-

-

-

-

-

-

Provision for income taxes

0

-22

-51

-60

-19

-192

0

0

0

-

-

-

-

-

-

-

-

Net loss

-8,262

-20,263

-31,033

-23,962

-22,078

-16,994

-15,958

-13,618

-15,086

-6,861

-9,090

-2,684

-11,435

-4,578

-1,115

2,322

-888

Other comprehensive income (loss):
Net income attributed to participating securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

2,141

-

Net loss attributed to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,115

181

-

Unrealized income on available for sale securities, net of tax of $0 and $115, respectively

807

-142

-94

370

427

744

136

124

-801

-383

16

-46

-13

0

0

0

0

Other comprehensive income (loss), net of tax

-

-

-

-

-

-

-

-

-

-

16

-46

-13

0

0

0

0

Comprehensive loss

-7,455

-20,405

-31,127

-23,592

-21,651

-16,250

-15,822

-13,494

-15,887

-7,244

-9,074

-2,730

-11,448

-2,437

-1,115

181

-888

Net loss per common share:
Basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.42

0.07

-

Diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.42

0.05

-

Basic and diluted (in dollars per share)

-0.30

-0.74

-1.15

-0.89

-0.82

-0.64

-0.66

-0.57

-0.63

-0.19

-0.45

-0.13

-0.75

-

-

-

-0.34

Weighted-average number of shares outstanding:
Basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,636

2,635

-

Diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,636

3,498

-

Basic and diluted (in shares)

27,264

27,171

27,058

27,026

26,981

26,813

24,146

23,932

23,801

23,180

20,382

20,271

15,295

-

-

-

2,629